Ascentage Pharma Group International (AAPG) Common Equity (2023 - 2025)

Ascentage Pharma Group International's Common Equity history runs 4 years deep, the most recent figure standing at $186.7 million for Q4 2025.

• In Q4 2025, Common Equity rose 389.26% year-over-year to $186.7 million; the TTM figure through Dec 2025 stood at $186.7 million (up 389.26% YoY), while the FY2025 annual figure was $190.8 million, up 657796.55% from the prior year.
• Common Equity for Q4 2025 stood at $186.7 million, up from $38.2 million in the prior quarter.
• The five-year high for Common Equity was $186.7 million in Q4 2025, with the low at $9.8 million in Q4 2023.
• The 4-year median for Common Equity is $47.8 million (2022), against an average of $73.0 million.
• The sharpest annual moves came in 2023 and 2025: Common Equity plunged 82.93% in 2023, then soared 389.26% in 2025.
• Ascentage Pharma Group International's Common Equity stood at $57.5 million in 2022, then slumped by 82.93% to $9.8 million in 2023, then soared by 289.07% to $38.2 million in 2024, then surged by 389.26% to $186.7 million in 2025.
• Business Quant data shows AAPG's Common Equity at $186.7 million in Q4 2025, $38.2 million in Q4 2024, and $9.8 million in Q4 2023.